Biotech vs Pharma: What’s the Difference, and How Do They Work Together?

Biotech vs Pharma: The Short Answer

A biotech company develops medicines and technologies using biology: living cells, proteins, antibodies, genes and other biological systems. Most biotechs are young, research-focused companies with one technology platform or a few drug candidates, no product revenue yet, and funding from venture capital, public markets and partnerships.

A pharmaceutical company, or pharma company, was historically defined by chemistry: it made drugs by chemical synthesis. Today the term usually describes a large, integrated company that discovers, develops, manufactures and sells many medicines worldwide, and funds its research from the sales of products already on the market.

The most useful difference today is the business model rather than the science. Biotechs take concentrated scientific risk to create new medicines; pharma companies take those medicines through late-stage development and to patients at global scale. Each needs the other, which is why the industry increasingly calls itself “biopharma.”

How the Two Industries Began

The pharmaceutical industry is much older. Many of today’s large pharma companies grew out of 19th-century chemical, dye and apothecary businesses in Europe and the US, and for most of the 20th century they discovered medicines by synthesizing and screening chemical compounds. That model produced most of the tablets and capsules in use today.

The biotech industry began in the 1970s with recombinant DNA, the technique that lets bacteria or cells produce human proteins. Genentech, founded in South San Francisco in 1976 and widely regarded as the first biotechnology company, used it to make human insulin, which Eli Lilly brought to market as Humulin in 1982. A wave of companies followed, building medicines from antibodies, hormones and enzymes that chemistry could not make.

Over the following decades the two industries converged. Pharma companies built or bought biologics capabilities, and successful biotechs grew into large commercial companies. Today the distinction is less about where a company started and more about its size, its funding and its role in getting a medicine to patients.

The Science: Biologics vs Small Molecules

The original distinction was about how a medicine is made. Small-molecule drugs are chemically synthesized compounds, such as most tablets and capsules. In the US they are approved through a new drug application (NDA) under the Federal Food, Drug, and Cosmetic Act, and their copies are generics.

Biologics are made in or from living systems: therapeutic proteins and antibodies, vaccines, blood products and cell and gene therapies. The FDA describes them as generally large, complex molecules that are harder to characterize than chemically synthesized drugs. They are licensed through a biologics license application (BLA) under the Public Health Service Act, and their follow-on versions are biosimilars rather than generics, as our Humira biosimilar list shows.

Biotech companies pioneered biologics, starting with Genentech in 1976, and they still lead most of the newest modalities, from antibody-drug conjugates to RNA medicines and gene therapies. But large pharma companies now develop and sell biologics on a huge scale, and many biotechs work on small molecules. Science alone no longer tells you which kind of company you are looking at.

The Business Model

A typical biotech spends money for years before it earns any. It raises venture capital to fund research and early trials, may list on a stock exchange to fund later trials, and often signs partnerships that bring in upfront and milestone payments. Its value rises and falls with its data, and most biotechs end in one of three ways: a licensing deal for their lead asset, an acquisition, or, less often, building their own commercial business.

A typical pharma company earns most of its revenue from a portfolio of marketed products, maintains global sales, regulatory and manufacturing organizations, and spends billions on research each year. Its central problem is replacement: every major product eventually loses patent protection, and its sales fall sharply when generics or biosimilars arrive. Evaluate estimates that the ten largest upcoming patent expiries alone put about $126 billion of annual sales at risk. Our analysis of the patent cliff covers which products are exposed.

Who Discovers New Drugs

Biotechs now originate most new medicines. According to the Biotechnology Innovation Organization, emerging biotech companies were behind 36 of the 54 novel drugs the FDA approved in 2024, about two-thirds of the total. Many of those drugs were later developed or sold with, or by, larger companies.

That does not make pharma less important. Large companies run most of the late-stage trials that need thousands of patients, build the manufacturing capacity, negotiate with payers in dozens of countries and run the sales forces that reach doctors. The most common path for a new drug is therefore a relay: discovered and proven early by a biotech, then developed and launched with a pharma partner.

For anyone sourcing new medicines, the practical consequence is that the search has to cover thousands of biotech companies rather than a few dozen large ones, and increasingly companies outside the US. A growing share of the assets that pharma licenses now comes from biotechs in China, Europe and other parts of Asia, which is why cross-border scouting has become a standard part of pharma business development.

How Biotech and Pharma Work Together

The relay runs through four main kinds of transaction.

• Licensing. A pharma company takes the rights to a biotech’s drug, in some or all territories, for an upfront payment, milestones and royalties. Our in-licensing vs out-licensing guide explains the basics.
• Co-development and partnerships. The two share costs and profits, or split responsibilities by region or stage, as our biotech partnerships guide describes.
• Options. Pharma pays for the right to license or acquire later, once more data are available.
• Acquisitions. Pharma buys the whole company. J.P. Morgan counted $122.1 billion of biopharma M&A upfront value in 2025 and $138.9 billion in the first nine months of 2026.

Valuing these deals relies on the same tools on both sides of the table, set out in our rNPV valuation guide and term sheet guide.

How a Drug Moves From Biotech to Pharma

A typical path for a new medicine shows how the two roles fit together.

1. Discovery. A university lab identifies a new target or molecule, and the technology-transfer office licenses it to a start-up.
2. Company formation. Founders and venture investors form a biotech to develop the molecule through preclinical studies.
3. Early clinical trials. The biotech runs Phase 1 and Phase 2 trials, funded by further venture rounds or a public listing, to show the drug is safe and works in patients.
4. The deal. With proof-of-concept data, the biotech licenses the drug to a pharma company, signs a co-development partnership, or is acquired.
5. Late-stage development and launch. The pharma partner runs the large Phase 3 trials, files for approval in major markets, builds manufacturing and launches the drug.
6. Loss of exclusivity. When patents expire, generics or biosimilars enter, and the pharma company looks for the next biotech asset to replace the lost revenue.

Not every drug follows this path. Some biotechs take their drugs all the way to market, and pharma companies still discover many medicines in their own laboratories. But the relay is common enough to explain much of the industry’s deal activity. Our guide to drug development stages describes each step in detail.

Big Biotechs and Biotech-Minded Pharma

The labels can mislead. Some of the world’s largest drug companies still call themselves biotechs because of where they started: Amgen, Gilead Sciences, Regeneron and Vertex all sell medicines globally, run large commercial organizations and acquire smaller companies, much like pharma. At the same time, pharma groups have absorbed biotech culture: Roche has owned Genentech outright since 2009 but still runs it as a distinct research organization in South San Francisco.

For practical purposes, ask two questions instead of reading the label. Does the company fund its research from its own product sales? And does it have the capability to develop, make and sell a drug globally on its own? If both answers are yes, it behaves like pharma, whatever it calls itself.

Biotech vs Pharma in China

China shows how quickly the line can move. Its traditional pharmaceutical industry was built on generics; over the past decade, established groups such as Hengrui have turned into innovative drug developers, while a new generation of biotechs, including BeiGene (now BeOne Medicines), Akeso and Innovent, has grown into global players. Our list of the top Chinese biotech companies profiles the leaders.

Both kinds of Chinese company now license their discoveries to Western pharma. Chinese out-licensing reached a record of roughly $136 billion in total deal value in 2025, according to our China Out-Licensing Report 2026, making China one of the largest external sources of new drug candidates for global pharma.

What Each Side Looks For

When a biotech and a pharma company sit down to discuss a deal, each is assessing the other against a familiar list.

What pharma looks for in a biotech asset: clinical data that clearly differentiate the drug from existing treatments and competitors; strong, long-lasting patents; a manufacturing process that can scale; a development path the regulators will accept; and a fit with the therapeutic areas and revenue gaps the company has said it wants to fill. Our pharma due diligence checklist lists what buyers examine.

What a biotech looks for in a pharma partner: commitment to the asset, shown by the size of the upfront payment and the development obligations it will accept; the capability to run large trials and launch in key markets; fair economics on milestones and royalties; and a team that will keep the program a priority after the deal is signed. A partner that buys a drug and then deprioritizes it can be worse than no partner at all.

Related Terms You Will See

Biopharma

The combined biotech and pharmaceutical industry; often used for any company developing medicines.

Emerging biotech

A smaller, usually pre-revenue company focused on research and early development.

Specialty pharma

A mid-sized company focused on particular therapeutic areas or on improving existing drugs.

Generics and biosimilars companies

Companies that make copies of drugs after patents expire: generics for small molecules, biosimilars for biologics.

CRO and CDMO

Service companies that run research and clinical trials (CROs) or develop and manufacture drugs (CDMOs) for both biotech and pharma; see our CRO vs CDMO guide.

Medtech

Companies that make medical devices and diagnostics rather than medicines.

Life sciences

The broadest term, covering biotech, pharma, medtech, research tools and related services.

Working in Biotech vs Pharma

For people choosing between the two, the differences are mostly about scope, pace and risk.

• Biotech roles tend to be broader, decisions faster and teams smaller. Equity can be valuable if the company succeeds, but jobs are less secure: a failed trial or a tight funding market can force cuts.
• Pharma roles tend to be more specialized, with deeper resources, structured training and clearer career paths, and exposure to large-scale development, manufacturing and commercialization that small companies cannot offer.

Many careers move between the two: experience at a large company is valued by biotechs building their first late-stage or commercial teams, and biotech experience is valued by pharma business-development and research groups.

Investing in Biotech vs Pharma

The same differences show up in the stock market. Shares in clinical-stage biotechs move sharply on trial results, regulatory decisions and financing news, because a single event can change a company’s value. Large pharma shares tend to move with the performance of a broad product portfolio, upcoming patent expiries and deal activity, and many pay regular dividends. This is general context, not investment advice; our biotech venture capital guide explains how private investors approach the sector.

The Bottom Line

Biotech and pharma are best understood as two roles in one industry. Biotechs take focused scientific risk and now originate most new medicines; pharma companies bring the capital, scale and reach to develop and sell them worldwide. The connection between the two, through licensing, partnerships and acquisitions, is where much of the industry’s value is created, and increasingly it crosses borders between the US, Europe and Asia.

If you are a biotech looking for the right pharma partner, or a pharma team looking for the right asset, talk to our team.